Activated immune cells after liver tumor removal for HCC
Part of Cancer, Digestive system clinical trials.
This Phase 2 study tests an immune-cell treatment (activated T lymphocytes) given after your liver cancer tumor has been fully removed. It aims to improve safety and reduce the chance of the cancer coming back in people with early-stage hepatocellular carcinoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 20 years or older and able to understand and sign consent.
- You have liver cancer (HCC) in stage I, II, or IIIa, confirmed by biopsy or imaging, and your tumor has been completely removed with curative treatment within about 12 weeks.
- Your liver is functioning well enough for Child-Pugh class A, and you must be able to do daily activities with ECOG score 1 or less.
- Your blood, kidney, and liver test numbers must meet limits (for example: ANC at least 1,500/µL, hemoglobin at least 9.0 g/dL).
- You must be able to have CT or MRI scans around the study times.
- If you can become pregnant (or partner with someone who can): you must use acceptable birth control during the study and for at least 24 weeks after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests using your own immune cells (tumor-infiltrating lymphocytes) to fight advanced liver cancer. It may help if you have Barcelona Clinic Liver Cancer (BCLC) stage B or C and your liver function is still fairly good.
This trial tests a custom immune-cell treatment made to target a marker (GPC3) found on some liver cancers. It’s for adults with advanced HCC whose cancer has worsened after standard treatment or who couldn’t tolerate it.
This study is testing whether combining targeted therapy with immunotherapy can help people with advanced liver cancer that cannot be surgically removed. The goal is to see if this combination treatment is safe and effective.
This Phase 2 trial studies durvalumab and tremelimumab (immunotherapy medicines) in people with resectable early or intermediate-stage liver cancer (HCC). It aims to see how well these medicines work before/around the time of surgery, and whether they can improve outcomes.
This trial tests a combination of focused radiation (SBRT), an immunotherapy drug (adelimumab), and a targeted therapy pill (apatinib) before surgery for liver cancer. The goal is to shrink tumors enough to make surgery possible or more effective.
This study looks at how your immune cells respond to two specific immunotherapy-based treatments for advanced liver cancer. Researchers want to understand why some patients respond well and others do not, which could help improve future care.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.